Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).